QFR® identified additional lesions at risk for future nontarget vessel–related events in STEMI through 5 years of follow up.
Dr Sarah Bär et al from Univ of Bern, Switzerland carried out a retrospective QFR analysis of untreated nontarget vessels from the COMFORTABLE AMI Trial in 946 vessels from 617 patients. Conclusion: in STEMI-patients undergoing angiography-guided complete revascularization of all nonculprit lesions with ≥70% stenosis by visual estimate, QFR identified additional lesions at risk for future nontarget vessel–related events through 5 years of follow-up.
Read the article here
Learn more on the benefits of QFR®
